ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.
about
The epigenetic landscape of acute myeloid leukemiaASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repressionAcute Myeloid Leukemia: A Concise ReviewRevealing the Complexity of Breast Cancer by Next Generation SequencingGenomics-based Approach and Prognostic Stratification Significance of Gene Mutations in Intermediate-risk Acute Myeloid LeukemiaMolecular Genetic Markers in Acute Myeloid LeukemiaMolecular prognostic factors in cytogenetically normal acute myeloid leukemiaCIViC databaseNext generation sequencing of acute myeloid leukemia: influencing prognosis.Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome.ASXL1 mutations define a subgroup of patients with acute myeloid leukemia with distinct gene expression profile and poor prognosis: a meta-analysis of 3311 adult patients with acute myeloid leukemia.Novel Prognostic and Therapeutic Mutations in Acute Myeloid LeukemiaEpigenetics in Cancer: A Hematological PerspectiveSignificance of oncogenes and tumor suppressor genes in AML prognosis.Inhibition of EZH2 degradation as a novel approach to overcome drug resistance in acute myeloid leukemia.Acute myeloid leukemia in the elderly is characterized by a distinct genetic and epigenetic landscape.Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia.Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivoGenome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia.GAS6 expression identifies high-risk adult AML patients: potential implications for therapyMolecular therapy for acute myeloid leukaemia.ASXL genes and RUNX1: an intimate connection?Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocations.Mutation patterns of 16 genes in primary and secondary acute myeloid leukemia (AML) with normal cytogenetics.Functional proteomics of the epigenetic regulators ASXL1, ASXL2 and ASXL3: a convergence of proteomics and epigenetics for translational medicine.Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia.DNMT3A Mutational Status Affects the Results of Dose-Escalated Induction Therapy in Acute Myelogenous LeukemiaExpression and prognostic impact of lncRNAs in acute myeloid leukemia.Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center.ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study Group.Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemiaIntegrated genomic profiling, therapy response, and survival in adult acute myelogenous leukemiaResidual Disease in a Novel Xenograft Model of RUNX1-Mutated, Cytogenetically Normal Acute Myeloid LeukemiaRole of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes.A Modified Integrated Genetic Model for Risk Prediction in Younger Patients with Acute Myeloid Leukemia.miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemiaThe Globalization of Cooperative Groups.Is targeted therapy feasible in acute myelogenous leukemia?
P2860
Q21284742-1CB50893-F147-46B5-8FAB-182C707B1587Q24296658-03D6CE80-0AF0-4D98-AD31-CB9D367DC9A9Q26766719-DAB2B2F6-1724-427B-BFC3-1645230D0C09Q26777395-94986AEB-ABC7-4F32-B7D5-67C8EBFA6FEAQ26796514-EA0D54F0-F0F6-4145-8AE1-766133F886FDQ26799606-17D467F3-706E-45C2-9AE0-AB1ECE258F5CQ26998811-6183EA48-5C39-4744-B67A-AD01C9F21C14Q27612411-1712DA32-1162-4C70-841A-578318EC42AAQ27690776-EF1737F1-F5FE-4BCA-A130-8395258EA2D4Q27851726-2156DEF2-335F-413E-8AFF-FEBC24429605Q27851839-177714D9-4CC3-43EA-9303-7C466B539370Q27851909-D86BB4B8-FB30-4D1C-802B-8996A5BF935AQ27853083-9CD87D68-CC29-49B4-8E9F-E318B1DCF6EDQ28075654-16C4B960-BD06-4374-8769-301521C130B7Q28077082-01D990F1-03A1-4938-AE4F-887856FEAEE4Q30250315-51CBFFE8-9C06-4F9F-8DB3-C22FEB16A568Q30313260-C2C1056A-C579-4DA3-B69B-9889369F654CQ30313288-59246E29-B56C-49EC-AA18-499451FCFD23Q30313615-5FCC8993-A199-4CBB-97C7-14BCCE1D44A7Q30413034-260D90F1-A35A-49A0-9A5B-3D0EC8D22E67Q30449092-DF81405C-0A69-4F05-89AA-22447B4E8C3CQ33717707-1EC7778D-C708-473B-9B8C-0C1EB401FC7DQ33925672-1E8BCEAB-ABB6-4CF8-8693-821682B435D1Q34106779-3F179221-F6D4-46C2-A94B-5F875C636EA1Q34106837-9BD35E25-F556-47F2-AB71-07EEFE9EDC90Q34388734-71BD26B7-BE31-4EE2-9A35-D4FEF4C280C6Q34469971-E6474730-212D-4BCC-B09C-DE6B26E83DD8Q34651312-617F6379-8A31-4436-A1BB-C19ED5BB45ABQ34667618-39FDAA09-114E-42AB-B6B4-CF1827142054Q34831106-FD989D2F-1FDA-4C0D-8D0E-744143EB69FBQ35054435-7A8D04DB-E92D-4429-B9C2-47BC27B21A04Q35146279-327544F1-8409-4E74-A94D-971E99AA6006Q35152173-8713CC40-C7D7-4F93-99E4-713E24EDE1FFQ35562821-4F14A6B9-6650-474E-A351-70FD731B6228Q35692708-17E258C0-B9EE-4F8A-B9D9-EB16EAF67D53Q35781605-EC3D23D6-ABA5-4859-92EF-F33EC628756EQ35981082-9568BCA5-D2F1-473A-A451-3C6D2CD36708Q36100455-930A0839-8A11-45C8-A1A7-9869FD7254A4Q36119749-D3040148-7540-479C-A307-44412F6C3CB1Q36416358-141629DC-0834-4937-8C6D-4D63B40FABEF
P2860
ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.
description
2011 nî lūn-bûn
@nan
2011 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
ASXL1 mutations identify a hig ...... LN Favorable genetic category.
@ast
ASXL1 mutations identify a hig ...... LN Favorable genetic category.
@en
ASXL1 mutations identify a hig ...... LN Favorable genetic category.
@nl
type
label
ASXL1 mutations identify a hig ...... LN Favorable genetic category.
@ast
ASXL1 mutations identify a hig ...... LN Favorable genetic category.
@en
ASXL1 mutations identify a hig ...... LN Favorable genetic category.
@nl
altLabel
ASXL1 mutations identify a hig ...... ELN Favorable genetic category
@en
prefLabel
ASXL1 mutations identify a hig ...... LN Favorable genetic category.
@ast
ASXL1 mutations identify a hig ...... LN Favorable genetic category.
@en
ASXL1 mutations identify a hig ...... LN Favorable genetic category.
@nl
P2093
P2860
P50
P3181
P1433
P1476
ASXL1 mutations identify a hig ...... LN Favorable genetic category.
@en
P2093
Andrew J Carroll
Bayard L Powell
Deedra Nicolet
Heiko Becker
Jonathan E Kolitz
Joseph O Moore
Maria R Baer
Meir Wetzler
Michael A Caligiuri
Michael D Radmacher
P2860
P304
P3181
P356
10.1182/BLOOD-2011-08-368225
P407
P50
P577
2011-12-22T00:00:00Z